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Abstract
Background: Few cross-sectional studies involving adults and elderly patients with major DDIs have been conducted in the
primary care setting. The study aimed to investigate the prevalence of potential drug-drug interactions (DDIs) in patients
treated in primary care.
Methodology/Principal Findings: A cross-sectional study involving patients aged 45 years or older was conducted at 25
Basic Health Units in the city of Maringa´ (southern Brazil) from May to December 2010. The data were collected from
prescriptions at the pharmacy of the health unit at the time of the delivery of medication to the patient. After delivery, the
researcher checked the electronic medical records of the patient. A total of 827 patients were investigated (mean age: 64.1;
mean number of medications: 4.4). DDIs were identified in the MicromedexH database. The prevalence of potential DDIs and
major DDIs was 63.0% and 12.1%, respectively. In both the univariate and multivariate analyses, the number of drugs
prescribed was significantly associated with potential DDIs, with an increasing risk from three to five drugs (OR = 4.74; 95%
CI: 2.90–7.73) to six or more drugs (OR = 23.03; 95% CI: 10.42–50.91). Forty drugs accounted for 122 pairs of major DDIs, the
most frequent of which involved simvastatin (23.8%), captopril/enalapril (16.4%) and fluoxetine (16.4%).
Conclusions/Significance: This is the first large-scale study on primary care carried out in Latin America. Based on the
findings, the estimated prevalence of potential DDIs was high, whereas clinically significant DDIs occurred in a smaller
proportion. Exposing patients to a greater number of prescription drugs, especially three or more, proved to be a significant
predictor of DDIs. Prescribers should be more aware of potential DDIs. Future studies should assess potential DDIs in
primary care over a longer period of time.
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Introduction
Treatment with drugs is an essential tool of modern health care,
but may also be a cause of illness and death, leading to a huge
economic burden for society [1]. Although the concurrent use of
multiple drugs often increases therapeutic effectiveness, certain
combinations are harmful [2] and the growing use of new
pharmacological agents has led to an increased risk of drug
interactions [3]. Drug interactions are common in older adults [4]
and usually result from shared metabolism pathways or intersect-
ing drug action pathways [5]. The drugs most commonly
implicated in major potential interactions are those used in the
day-to-day clinical management of elderly patients with chronic
diseases [6]. Given the wide variety of drugs prescribed [7], the
safety of medications in primary care is a topic of considerable
importance. Improvement in drug safety is essential in terms of
patient morbidity/mortality as well as in economic terms [1].
Prescribers in all fields of medicine must become more aware of
medication safety for older adults [8].
Studies on primary care report prevalence values for potential
drug-drug interactions (DDIs) ranging 12% to 80% [3,9–11] and
prevalence values for clinically relevant DDIs ranging from 1.9%
to 28.3% [2,3,9–13]. On the other hand, studies carried out in
different healthcare settings report lower prevalence values for
clinically relevant DDIs, ranging from 0.4% to 17.3% [14–24].
However, the studies cited differ with regard to patient charac-
teristics, features of the interaction analysis software and sample
size.
Few cross-sectional studies involving adults and elderly patients
with major DDIs have been conducted in the primary care setting.
Moreover, DDIs in ambulatory settings have not been widely
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studied [17]. In Brazil, a number of studies on clinically important
potential DDIs have been carried out in different settings. Studies
involving community-dwelling individuals report prevalence rates
ranging from 4.6 to 17.6% [20,24]. Studies conducted in hospital
settings report prevalence rates ranging from 0.6 to 18.3% [23,25–
27] and a study carried out in a primary health care unit reports a
prevalence rate of 6.8% [28]. To the best of our knowledge, this is
the first large-scale study on primary care carried out in Latin
America. The aim of the present study was to investigate the
prevalence of potential drug-drug interactions in patients aged 45
years or older treated in the primary care setting in southern
Brazil.
Methods
Setting and design
A cross-sectional observational study was conducted at all 25
Basic Health Units in the city of Maringa´, state of Parana´,
southern Brazil, from May to December 2010. The estimated
population of the city is 357,117 inhabitants.
Patients and data collection
A convenience sample involving 827 patients and their
respective prescriptions was determined for the data collection.
A researcher spent one day at each Basic Health Unit throughout
the period of service (7:30 am to 6 pm). Information was collected
from prescriptions at the pharmacy of the health unit at the time of
the delivery of medication to the patient. After delivery, the
researcher checked the electronic medical records to retrieve all
medications prescribed to the patient. All prescription drugs are
provided free by municipal healthcare service, except indapamide,
meloxicam, norfloxacin and rosuvastatin, which are not included
on the list of standard public health drugs. Prescription drugs, age
and gender were the variables of interest. All information was
recorded on a standardized form. The criteria for the inclusion of
patients were having been treated in primary care by the physician
of the Basic Health Unit, age 45 years or older and the use of at
least two drugs prescribed by a physician.
Organization and data quality
Two methods were used to ensure greater accuracy of the
findings. The data were first manually transferred to standardized
forms, then double entered into the Epi Data 3.1H (The EpiData
Association, Denmark, Europe) program and conferred patient by
patient twice. The results between methods were compared for
overall agreement.
Analysis of potential DDIs
All potential drug-drug interactions were identified in the
MicromedexH database (Thomson Reuters Inc., 2011. Micro-
medex Healthcare Series Greenwood Village/CO) according to
the degree of severity (contraindicated, major, moderate, minor)
and entered into the Epi Data 3.1H program. The interactions
were also analyzed for potential risk. All potential DDIs were
analyzed in pairs. When a pair of drugs was not available in the
MicromedexH database, the interaction was not analyzed.
Statistical analysis
The data were analyzed using the StatisticaH program version
8.0 (StatSoft Company Information, Tulsa, Oklahoma, USA). In
the univariate analyses of factors associated with potential drug-
drug interactions, the chi-square test was used for the comparison
of the groups. In the multivariate analysis, all variables with a p-
value of ,0.05 and all confounding variables were incorporated
into the model. The data were controlled for gender, age and
number of drugs. The odds ratio (OR) and respective confidence
interval (CI) was calculated in the multivariate analysis for each
variable. A p-value of ,0.05 was considered statistically signifi-
cant.
Ethical considerations
This study received approval from the Ethics Committee on
Research Involving Human Subjects, State University of Maringa´,
in accordance with Resolution 196/1996 of the Brazilian Ministry
of Health. Patient consent was waived (document 119/2010) due
to the fact that the study involved information from a secondary
database. Moreover, the team of researchers did not have contact
with the patients at any time during the study. The researchers
complied with Resolution 196/1996, ensuring complete confiden-
tiality and anonymity. The Center for Continuing Education and
Training of Health Workers (CECAPS)/Municipal Department of
Health also approved this study.
Results
From May 1 to December 29, 2010, 827 patients aged 45 years
or older were investigated at 25 Basic Health Units for the
identification of potential drug-drug interactions. Most patients
were between 45 and 69 years of age (70.1%; mean age:
64.1610.6 years) and female (65.9%). The number of concomitant
prescription medications ranged from 2 to 11 (mean: 4.461.8) and
43.1% of patients took more than four drugs. Among the 827
patients, 521 had a potential DDI, resulting in a prevalence value
of 63.0%. More than three fifths (320/521) of these patients had
one to two potential DDIs (mean 2.561.9). The prevalence of
major DDIs was 12.1% (100/827) and among these 100 patients,
81.0% had at least one potential DDI (Table 1).
No statistically significant differences were found regarding the
presence/absence of potential DDI between men and women
(p = 0.61) or different age groups (p.0.05). In both the univariate
and multivariate analyses, the number of drugs prescribed was
significantly associated with potential DDIs, with an increasing risk
from three to five drugs (OR = 4.74; 95% CI: 2.90–7.73) to six or
more drugs (OR = 23.03; 95% CI: 10.42–50.91) (Table 2).
A total of 160 active substances were prescribed to patients, 16
of which were not analyzed in the MicromedexH database, thereby
enabling the assessment of 90%. Forty active substances accounted
for 122 pairs of major potential DDIs, classified as Drug A and
Drug B. The drugs of Group A most involved in major potential
DDIs were simvastatin (23.8%), captopril/enalapril (16.4%) and
fluoxetine (16.4%). Drugs acting on the cardiovascular system
(CVS) accounted for 69.0% of potential major DDIs and those
acting on the central nervous system (CNS) accounted for 28.5%
(Table 3)
Table 4 displays data regarding the 521 patients with potential
DDIs. For all age groups, potential moderate DDIs were the most
frequent (70.2%), followed by potential major DDIs (19.2%). The
age group with the highest frequency of potential major DDIs was
45 to 69 years (70.0%).
Discussion
The mean age of the sample (64 years) was similar to that
reported in other studies conducted on primary care (62 to 69
years) [2,11]. The mean number of prescription drugs was 4.4,
which is was consistent with a study conducted in similar settings
in Italy (4.3 drugs) [29]. Approximately 43% of the patients were
prescribed more than four drugs, which is similar to the
Prescription Pattern of Antihypertensive Drugs
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frequencies reported in previous studies (30.4% to 50.5%) [11,29].
Although the relative frequency in the present study is consistent
with the two studies cited, it should be stressed that mean age and
number prescription drugs were different.
The prevalence for all potential DDIs in patients treated in the
primary care setting was 63%. Rates ranging from 9.2% to 78.8%
have been described in patients under ambulatory care for all
potential DDIs [11,30]. This broad range of prevalence values
may be partially explained by factors such as study design,
methodology, definitions, characteristics of the population, num-
ber of medications prescribed, therapeutic traditions and com-
pendium of drug interactions [10,30,31].
In the present study, the prevalence of potential major DDIs
was 12.1% (100/827). This finding is in agreement with that
described in studies involving ambulatory patients, which report
values ranging from 3.8% to 16% [11,12,14,29]. Population-based
studies report prevalence values ranging from 10% to 17.6%
[10,20]. Major DDIs are considered clinically important and
should be avoided by healthcare professionals, especially physi-
cians and pharmacists. Pharmacists, in particular, should avoid
dispensing combinations of drugs that may have serious DDIs
[32]. In the present study, only 0.4% of the patients (3/827) had
contraindicated DDIs, which is similar to figures reported in
studies carried out in France (0.4%) [33] and Taiwan (0.2%) [18].
A previous population-based study conducted in Brazil using the
same database found a frequency of 2.4% [20]. Although this
result is much higher than the frequency found in the present
study, the difference may partially be explained by the study
design and characteristics of the population.
No statistically significant differences were found between men
and women regarding DDIs, which is consistent with findings
described in previous studies carried out in primary care settings
[11,29,34] as well as investigations carried out in other settings
[35,36]. Age is another important variable to consider in relation
to drug use. In the present study, no statistically significant
independent association was found regarding age, which is in
agreement with a number of studies conducted in different settings
[20,22,37] and in disagreement with other studies that report a
Table 1. General patients characteristics attendance in
primary care.
Variable Frequency (%)
Gender
Female 545 (65.9)
Male 282 (34.1)
Age (mean ± SD) 64.1610.6
45–59 298 (36.0)
60–69 282 (34.1)
70–79 172 (20.8)
$80 75 (9.1)
Drugs (mean ± SD) 4.461.8
2 109 (13.2)
3–4 361 (43.7)
5–6 245 (29.6)
.7 112 (13.5)
Number of DDIsa per patient (mean ± SD) 2.561.9
1 203 (39.0)
2 117 (22.5)
3 96 (18.4)
4–5 64 (12.3)
6–14 41 (7.8)
Number of major DDIs per patient (mean ± SD) 1.260.5
1 81 (81.0)
2 16 (16.0)
3 3 (3.0)
aDrug-drug interaction.
doi:10.1371/journal.pone.0047062.t001
Table 2. Predictors of potential drug-drug interactions in patients attendance in primary care (n = 827).
Potential drug-drug
interactions Univariate analysis Multivariate analysisa
Yes (%) No (%) OR (95% CI) p value OR (95% CI) p value
Sex
Male 181 (34.7) 101 (33.0) 1 1
Female 340 (65.3) 205 (67.0) 1.08 (0.80–1.46) 0.61 1.10(0.78–1.41) 0.56
Age (Year)
45–64 268 (51.5) 165 (53.9) 1 1
65–69 94 (18.0) 53 (17.3) 1.09 (0.74–1.61) 0.66 1.05 (0.69–1.58) 0.55
70–74 66 (12.7) 40 (13.1) 1.02 (0.66–1.57) 0.94 1.00 (0.62–1.55) 0.84
75–79 44 (8.4) 22 (7.2) 1.23 (0.71–2.13) 0.46 1.26 (0.75–2.21) 0.29
$80 49 (9.4) 26 (8.5) 1.16 (0.69–1.94) 0.57 1.11 (0.67–1.90) 0.53
Number of drugs
2 27 (5.2) 82 (26.8) 1 1
3–5 312 (59.9) 200 (65.4) 4.74 (2.90–7.73) ,0.001 4.84 (2.85–7.91) ,0.001
6 or more 182 (34.9) 24 (7.8) 23.03 (10.42–50.91) ,0.001 25.11 (9.98–48.63) ,0.001
aAdjusted for sex, age (year) and number of drugs. OR = odds ratio; CI = confidence interval.
doi:10.1371/journal.pone.0047062.t002
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positive association between age and potential DDIs
[11,20,29,38].
Three or more drugs prescribed to patients was significantly
associated with potential DDIs. Similar studies report a trend of
increasing prevalence of potential DDIs with the increase in the
number of drugs prescribed [11,29,33]. Research worldwide has
shown that polypharmacy (5 or more drugs) [39] contributes to the
increased risk of potential DDIs [18,19] In the present study,
approximately two fifths of the patients were taking five or more
drugs. The increasing prevalence of potential interactions with age
reflects the increase in the number of prescriptions [33]. The
number of drugs prescribed and used by patients is a significant
predictor of potential DDIs in pharmacoepidemiological studies.
Thus, steps should be taken to promote rational therapy in
primary care.
The three most active substances involved in potentially
clinically significant interactions were simvastatin, captopril/
enalapril and fluoxetine. Simvastatin, which is used to control
elevated cholesterol levels, is one of the most widely prescribed
drugs [40]. However, it requires considerable care and vigilance,
as it may expose patients to an increased risk of myopathy or
rhabdomyolysis [2,16,41–44]. Moreover, when used in combina-
tion with drugs with a potential DDI, the risk is even greater. An
older age is a risk factor for rhabdomyolysis among statin users.
Patients at high risk for developing rhabdomyolysis should be
closely monitored for signs and symptoms of the disease [44].
Captopril/enalapril in combination with potassium-sparing drugs
Table 3. Frequency of pairs of major potential drug-drug interactions in prescriptions dispensed in primary care (n = 122).
Drug A Drug B Frequency (%) Potential risk
Amitriptyline,
Nortriptyline Clonidine 2 (1.6) Decreased antihypertensive effectiveness
Atenolol Clonidine 5 (4.1) Increased risk of sinus bradycardia; exaggerated clonidine withdrawal
response (acute hypertension).
Atenolol Diltiazem 1 (0.8) Increased risk of hypotension, bradycardia, AV conduction disturbances.
Bromazepam Phenobarbital 1 (0.8) Aadditive respiratory depression.
Captopril Allopurinol 2 (1.6) Hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions).
Captopril Potassium 1 (0.8) Hyperkalemia.
Captopril, Enalapril Spironolactone 20 (16.5) Hyperkalemia.
Lithium Hydrochlorothiazide 1 (0.8) Increased lithium concentrations and lithium toxicity (weakness, tremor,
excessive thirst, confusion).
Lithium Chlorpromazine 1 (0.8) Weakness, dyskinesias, increased extrapyramidal symptoms,
encephalopathy, and brain damage.
Cilostazol Acetylsalicylicacid (AAS) 1 (0.8) Increased risk of bleeding.
Clonidine Propranolol, Verapamil 3 (2.5) Increased incidence of sinus bradycardia.
Digoxin Hydrochlorothiazide, Indapamide,
Amiodarone, Spironolactone,
15 (12.3) Digoxin toxicity (nausea, vomiting, cardiac arrhythmias).
Enalapril Allopurinol 2 (1.6) Hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions,
anaphylactic coronary spasm).
Fluoxetine AAS, Meloxicam, Diclofenac,
Ibuprofen
20 (16.5) Increased risk of bleeding
Fluoxetine Fluconazole 1 (0.8) Increased risk of cardiotoxicity (QT prolongation, torsades de pointes,
cardiac arrest).
Fluoxetine Imipramine, Nortriptyline 2 (1.6) Tricyclic antidepressant toxicity (dry mouth, urinary retention, sedation)
and an increased risk of cardiotoxicity (QT prolongation, torsades de
pointes, cardiac arrest).
Fluoxetine Haloperidol 1 (0.8) Haloperidol toxicity (pseudoparkinsonism, akathisia, tongue stiffness)
and an increased risk of cardiotoxicity (QT prolongation, torsades de
pointes, cardiac arrest).
Ginkgo Biloba Ibuprofen 2 (1.6) Increased risk of bleeding.
Haloperidol Amitryptiline, Imipramine,
Chlorpromazine
4 (3.3) Increased risk of cardiotoxicity (QT prolongation, torsades de pointes,
cardiac arrest).
Insulin (NPH),
Metformin
Ciprofloxacin, Norfloxacin 3 (2.5) Changes in blood glucose and increased risk of hypoglycemia or
hyperglycemia.
Propranolol Haloperidol 1 (0.8) Increased risk of hypotension and cardiac arrest.
Rosuvastatin Ciprofibrate 1 (0.8) Increased risk of myopathy or rhabdomyolysis
Simvastatin Amiodarone, Ciprofibrate,
Ciprofloxacin, Diltiazem, Fluconazole
29 (23.9) Increased risk of myopathy or rhabdomyolysis.
Simvastatin Warfarin 1 (0.8) Increased risk of bleeding and an increased risk of rhabdomyolysis.
Sotalol Furosemide, Sulfamethoxazole/
Trimethoprim
2 (1.6) Increased risk of cardiotoxicity (QT prolongation, torsades de pointes,
cardiac arrest).
doi:10.1371/journal.pone.0047062.t003
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may increase the risk of hyperkalemia [15,45–49]. Fluoxetine
interacting with an anti-inflammatory agent may increase the risk
of bleeding [21,50–52]. The prescription of these drugs in
combination should always be carefully analyzed according to
risk/benefit ratio [7].
The largest number of active substances prescribed with major
DDIs were related to the CVS (diuretics, ACE inhibitors, digoxin,
beta-blockers and calcium channel blockers), which is similar to
findings described in studies carried out in different settings
[3,19,22]. An Italian study reports acetylsalicylic acid, digoxin and
enalapril as the most prescribed substances [29]. A study carried
out in Mexico City reports that drugs for the alimentary tract and
metabolism were the most commonly prescribed, whereas drugs
for diabetes accounted for only 6.7% versus 24.8% for drugs
acting on the CVS. A higher frequency of prescription drugs
acting on the CVS is expected among adults and elderly
individuals. The second class of drugs most involved with major
DDIs were those acting on the CNS, which is consistent with
findings described in a previous study [33]. Public health services
should have a standard list of drugs, respecting the epidemiological
characteristics and actual situation of each health service. If
prescribers have access to a wider array of drugs at the health
service, they could prescribe safer drugs with less of a chance of
potential DDIs.
The results of the present investigation are similar to those
described in international studies that show an exponential growth
in major DDIs. The prevention of clinically relevant interactions
in primary care is the responsibility of all healthcare professionals.
As treatment should offer the advantage of better pharmacother-
apy for patients, it is imperative for physicians to be more aware of
the risks involved when exposing patients to major DDIs. These
predictable interactions are the primary responsibility of the
prescriber rather than the patient and care must therefore be taken
to develop reliable prescribing strategies that can be continuously
monitored and revised [6]. A number of programs for analyzing
potential drug-drug interactions and technical information are
available. The collaboration of healthcare professionals regarding
this problem could reduce the impact of potential DDIs on public
health.
The present study has some limitations that should be
addressed. First, the study involved a convenience sample and
consisted of only one day of data collection at each Basic Health
Unit. Second, the analysis of the pairs of potential drug-drug
interactions was based on only one database. Three, the study was
conducted in only one type of setting and the results may not be
generalizable to other settings or patients in different age groups.
Despite these limitations, the present study offers important
information on the prescription of drugs with potential DDIs in
patients aged 45 years or older in primary care.
In conclusion, the findings of the present study showed that the
estimated prevalence of potential DDIs among adults and elderly
individuals was high, whereas clinically significant DDIs occurred
in a smaller proportion and within the rates reported in the
literature. Exposing patients to a greater number of prescription
drugs, three or more, proved to be a significant predictor of DDIs.
Future studies should assess potential DDIs in primary care over a
longer period of time.
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